Humana INC 8-K filings

Humana Inc. has finalized the transition date for its new CEO, Jim Rechtin, who will assume the role on July 1, 2024, while current CEO Bruce Broussard will transition to a strategic advisory role.

Humana reported first quarter earnings that exceeded expectations but revised its full-year GAAP EPS guidance downwards while affirming its adjusted EPS outlook, citing challenges in the Medicare Advantage market.

Humana Inc. held its annual stockholders meeting on April 18, 2024, where all director nominees were elected and several proposals were voted on.

Humana Inc. successfully priced and closed a $2.25 billion offering of senior notes to fund general corporate purposes and potentially repay existing debt.

Humana reaffirms its 2024 earnings guidance of approximately $14.87 diluted EPS and $16.00 adjusted EPS during investor meetings.

Humana anticipates a 1.6% negative impact on its benchmark funding due to proposed changes in Medicare Advantage payment rates, significantly worse than expected.

Humana reported a fourth-quarter loss and provided a lower-than-expected initial full-year 2024 financial guidance, citing increased Medicare Advantage medical costs.

Humana has revised its 2024 Medicare Advantage membership growth forecast and lowered its 2023 earnings per share guidance due to higher than anticipated medical costs.